We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
-9.51%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$486M
AUM Growth
+$102M
(+27%)
Cap. Flow
+$150M
Cap. Flow
% of AUM
30.89%
Top 10 Holdings %
Top 10 Hldgs %
40.72%
Holding
86
New
15
Increased
40
Reduced
9
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$21.9M |
| 2 |
Sanofi
SNY
|
+$18.6M |
| 3 |
Centene
CNC
|
+$16.6M |
| 4 |
DexCom
DXCM
|
+$15.2M |
| 5 |
Guardant Health
GH
|
+$14.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$15.5M |
| 2 |
Globus Medical
GMED
|
+$13.3M |
| 3 |
Acadia Healthcare
ACHC
|
+$9.83M |
| 4 |
AMED
Amedisys
AMED
|
+$6.89M |
| 5 |
Cigna
CI
|
+$5.99M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Inspire Medical Systems
INSP
$1.71B
| – | – |
-10,000
| Closed | -$2.57M |
|
77
Intuitive Surgical
ISRG
$142B
| – | – |
-16,000
| Closed | -$4.83M |
|
78
Keros Therapeutics
KROS
$211M
| – | – |
-81,000
| Closed | -$4.41M |
|
79
Neurocrine Biosciences
NBIX
$16.5B
| – | – |
-35,000
| Closed | -$3.28M |
|
|
80
Pfizer
PFE
$152B
| – | – |
-300,000
| Closed | -$15.5M |
|
81
PMV Pharmaceuticals
PMVP
$69.3M
| – | – |
-50,000
| Closed | -$1.04M |
|
82
Regenxbio
RGNX
$703M
| – | – |
-90,000
| Closed | -$2.99M |
|
83
Teleflex
TFX
$5.91B
| – | – |
-8,000
| Closed | -$2.84M |
|
|
CMRX
84
DELISTED
Chimerix, Inc.
CMRX
| – | – |
-119,000
| Closed | -$545K |
|
|
ICPT
85
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| – | – |
-125,000
| Closed | -$2.03M |
|
|
SRRA
86
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| – | – |
-30,000
| Closed | -$962K |
|
Similar funds
CL
ACM
ACG
NSUP
TP
ACP
TA
AG
Integral Health Asset Management's Q2 2022 Portfolio in Review
As of Q2 2022, Integral Health Asset Management held 86 positions worth $486M, up 27% from $384M the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Integral Health Asset Management deployed $150M of net new capital in Q2 2022, opening 15 new positions and adding to 40 existing holdings. Its largest new stake was Eli Lilly: 73,059 shares worth $23.7M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier.
On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $2.69M trimmed.
- Integral Health Asset Management's largest Q2 2022 buy was Eli Lilly: 73,059 shares worth $23.7M.
- Integral Health Asset Management added most to Centene in Q2 2022, an estimated $16.6M increase.
- Integral Health Asset Management's biggest Q2 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $2.69M.
- Integral Health Asset Management fully exited Pfizer in Q2 2022, selling an estimated $15.5M.
- Integral Health Asset Management's ten largest holdings make up 41% of its $486M portfolio in Q2 2022.
- Integral Health Asset Management opened 15 new positions and closed 21 in Q2 2022.
- Integral Health Asset Management's portfolio value rose 27% quarter-over-quarter to $486M.
Based on Integral Health Asset Management's 13F filing for Q2 2022, filed 3 Aug 2022.